Evidence map›Paper›PMID 26811028›Full record

ArticleJournal of neurochemistry2016

Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure.

Heather M Wilkins, Scott Koppel, Steven M Carl, Suruchi Ramanujan, Ian Weidling, Mary L Michaelis, Elias K Michaelis, Russell H Swerdlow

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  6. Article
  7. Article
  8. Lactate: A Theranostic Biomarker for Metabolic Psychiatry?Antioxidants (Basel, Switzerland) · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Aberrant Energy Metabolism in Alzheimer's Disease.Journal of translational internal medicine · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Heather M WilkinsDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Scott KoppelUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.ORCID http://orcid.org/0000-0001-9001-4454
Steven M CarlUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Suruchi RamanujanUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Ian WeidlingUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Mary L MichaelisUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Elias K MichaelisUniversity of Kansas Alzheimer's Disease Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Russell H SwerdlowDepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
University of Kansas Medical Center · USUniversity of Kansas · US

Funding

University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SWERDLOW, RUSSELL H. · 2011 to 2020
$16.6M
Oxaloacetate's Brain EffectsR03NS077852 · NINDS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SWERDLOW, RUSSELL H. · 2012 to 2013
$148k
NIA NIH HHS P30 AG035982NINDS NIH HHS NS077852NINDS NIH HHS R03 NS077852
6 · The paper itself

Abstract

We tested how the addition of oxaloacetate (OAA) to SH-SY5Y cells affected bioenergetic fluxes and infrastructure, and compared the effects of OAA to malate, pyruvate, and glucose deprivation. OAA displayed pro-glycolysis and pro-respiration effects. OAA pro-glycolysis effects were not a consequence of decarboxylation to pyruvate because unlike OAA, pyruvate lowered the glycolysis flux. Malate did not alter glycolysis flux and reduced mitochondrial respiration. Glucose deprivation essentially eliminated glycolysis and increased mitochondrial respiration. OAA increased, while malate decreased, the cell NAD+/NADH ratio. Cytosolic malate dehydrogenase 1 protein increased with OAA treatment, but not with malate or glucose deprivation. Glucose deprivation increased protein levels of ATP citrate lyase, an enzyme which produces cytosolic OAA, whereas OAA altered neither ATP citrate lyase mRNA nor protein levels. OAA, but not glucose deprivation, increased cytochrome oxidase subunit 2, PGC1α, PGC1β, and PGC1 related co-activator protein levels. OAA increased total and phosphorylated SIRT1 protein. We conclude that adding OAA to SH-SY5Y cells can support or enhance both glycolysis and respiration fluxes. These effects appear to depend, at least partly, on OAA causing a shift in the cell redox balance to a more oxidized state, that it is not a glycolysis pathway intermediate, and possibly its ability to act in an anaplerotic fashion. We examined how oxaloacetate (OAA) affects bioenergetic fluxes. To advance the understanding of how OAA mediates these changes, we compared the effects of OAA to malate, pyruvate, and glucose deprivation. We further examined how OAA affects levels of enzymes that facilitate its cytosolic metabolism, and found OAA increased the expression of malate dehydrogenase 1 (MDH1-cytosolic). We propose the following: OAA supports both glycolysis and respiration fluxes, shifts the cell redox balance toward a more oxidized state, and acts in an anaplerotic fashion. Abbreviations not defined in the text: MDH2, malate dehydrogenase 2 (mitochondrial).

Indexed as

Adenosine TriphosphateCell LineCell Line, TumorCytosolEnergy MetabolismGlucoseGlycolysisHumansMalate DehydrogenaseMalatesMitochondriaNADNeuroblastomaNeuronsOxaloacetic AcidOxygen ConsumptionAdenosine TriphosphateGlucoseMalate Dehydrogenasemalate dehydrogenase (decarboxylating)Malatesmalic acidNADOxaloacetic AcidPyruvic AcidRNA, Messengerbioenergeticsglycolysismitochondriaoxaloacetaterespiration

Identifiers

PMID26811028
PMCPMC5482267
OpenAlexW2260168947

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.